Literature DB >> 34269944

Additional Esophagectomy Following Noncurative Endoscopic Resection for Early Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Study.

Zhichao Liu1,2, Jie Zhang2,3, Yuchen Su2, Jie Pan1, Yang Yang1, Binhao Huang3, Jianqiang Zhao4, Zhigang Li5.   

Abstract

BACKGROUND: Esophagectomy is recommended after endoscopic resection (ER) for early esophageal squamous cell carcinoma (ESCC) when histopathological factors indicate a risk of nodal metastasis and incomplete resection. We aimed to analyze the outcomes of surgery management in this clinical setting and evaluate risk factors for residual disease after ER. PATIENTS AND METHODS: We conducted a retrospective review of cT1N0M0 ESCC patients with noncurative ER and additional esophagectomy (2009-2019, eight centers). Noncurative ER was defined as positive resected margins on pathology, lymphovascular invasion (LVI), poor differentiation, or submucosal invasion. The pathology after ER and esophagectomy was analyzed to identify predictors of nodal metastasis and residual tumor.
RESULTS: The study enrolled 128 patients. Primary residual tumor and nodal metastasis were confirmed in 25 (19.5%) and 15 (11.7%) patients, respectively. On multivariate analysis, nodal metastasis was independently associated with submucosal invasion [odds ratio (OR), 9.9; 95% CI, 1.1-96.1], LVI (OR, 20.9; 95% CI, 2.9-150.5), and tumor size ≥ 2 cm (OR, 8.1; 95% CI, 1.4-48.2) (all P < 0.05), but not with poor differentiation (P = 0.613). Regarding residual primary tumor, only positive vertical margin was significant factor (OR, 147; 95% CI, 18 to > 999; P < 0.001).
CONCLUSIONS: Additional esophagectomy after noncurative ER allowed the resection of residual tumor and nodal metastasis, with favorable outcomes. Close follow-up may be feasible for a positive horizontal margin alone or poor differentiation alone, whereas intensive treatment should be considered for patients with submucosal invasion, LVI, and a positive vertical margin, especially when combined with tumor size ≥ 2 cm. Prospective research is needed to confirm the optimal management after ER.
© 2021. Society of Surgical Oncology.

Entities:  

Year:  2021        PMID: 34269944     DOI: 10.1245/s10434-021-10467-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.

Authors:  Tsuyoshi Tanaka; Masaki Ueno; Toshiro Iizuka; Shu Hoteya; Shusuke Haruta; Harushi Udagawa
Journal:  Dis Esophagus       Date:  2019-12-31       Impact factor: 3.429

2.  Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer.

Authors:  Ryan P Merkow; Karl Y Bilimoria; Rajesh N Keswani; Jeanette Chung; Karen L Sherman; Lawrence M Knab; Mitchell C Posner; David J Bentrem
Journal:  J Natl Cancer Inst       Date:  2014-07-16       Impact factor: 13.506

3.  ASO Visual Abstract: Exposure to Blood Components and Inflammation Contribute to Pancreatic Cancer Progression.

Authors:  Ryo Saito; Hiromichi Kawaida; Naohiro Hosomura; Hidetake Amemiya; Jun Itakura; Atsushi Yamamoto; Koichi Takiguchi; Suguru Maruyama; Katsutoshi Shoda; Shinji Furuya; Hidenori Akaike; Yoshihiko Kawaguchi; Makoto Sudo; Shingo Inoue; Hiroshi Kono; Daisuke Ichikawa
Journal:  Ann Surg Oncol       Date:  2021-12       Impact factor: 5.344

  3 in total
  4 in total

1.  Computed tomography-based radiomics analysis to predict lymphovascular invasion in esophageal squamous cell carcinoma.

Authors:  Hui Peng; Qiuxing Yang; Ting Xue; Qiaoling Chen; Manman Li; Shaofeng Duan; Bo Cai; Feng Feng
Journal:  Br J Radiol       Date:  2021-12-15       Impact factor: 3.039

2.  Effects of pre-operative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy: protocol for a multicenter randomized controlled trial (point trial, pre-operative immunonutrition therapy).

Authors:  Yuqin Cao; Dingpei Han; Su Yang; Yongmei Shi; Shengguang Zhao; Qianwen Jin; Jian Li; Chengqiang Li; Yajie Zhang; Weiyu Shen; Jinxian He; Mingsong Wang; Guangyu Ji; Zhigang Li; Yi He; Qixun Chen; Weitian Wei; Chun Chen; Xian Gong; Jinyi Wang; Lijie Tan; Hao Wang; Hecheng Li
Journal:  BMC Cancer       Date:  2022-06-13       Impact factor: 4.638

3.  Can lymphovascular invasion be predicted by contrast-enhanced CT imaging features in patients with esophageal squamous cell carcinoma? A preliminary retrospective study.

Authors:  Yang Li; Haiyan Su; Li Yang; Meng Yue; Mingbo Wang; Xiaolong Gu; Lijuan Dai; Xiangming Wang; Xiaohua Su; Andu Zhang; Jialiang Ren; Gaofeng Shi
Journal:  BMC Med Imaging       Date:  2022-05-17       Impact factor: 2.795

4.  PCDH20 inhibits esophageal squamous cell carcinoma proliferation and migration by suppression of the mitogen-activated protein kinase 9/AKT/β-catenin pathway.

Authors:  Yijiao Ning; Chaoqun Deng; Chunhong Li; Weiyan Peng; Chun Yan; Jing Ran; Weihong Chen; Yujia Liu; Jiuyi Xia; Lin Ye; Zhengqiang Wei; Tingxiu Xiang
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.